Melatonin-B6 (Pyridoxal Phos)

Drug overview for MELATONIN-B6 (PYRIDOXAL PHOS) (melatonin/pyridoxal phosphate):

Generic name: melatonin/pyridoxal phosphate
Drug class: Vitamin B-6
Therapeutic class: Central Nervous System Agents

No enhanced Introduction information available for this drug.

No enhanced Uses information available for this drug.

DRUG IMAGES

No Image Available

The following indications for MELATONIN-B6 (PYRIDOXAL PHOS) (melatonin/pyridoxal phosphate) have been approved by the FDA:

Indications:
None.

Professional Synonyms:
None.

The following drug interaction information is available for MELATONIN-B6 (PYRIDOXAL PHOS) (melatonin/pyridoxal phosphate):

Contraindicated
Severe
Moderate

There are 0 contraindications.

There are 0 severe interactions.

There are 1 moderate interactions. The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.

Drug Interaction	Drug Names
Levodopa/Pyridoxine SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Pyridoxine increases levodopa metabolism, decreasing the amount of levodopa available to the central nervous system. CLINICAL EFFECTS: The pharmacologic effects of levodopa may be decreased. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Avoid pyridoxine in patients receiving levodopa alone; however, the interaction can be minimized by giving levodopa with a peripheral decarboxylase inhibitor (e.g. carbidopa, benserazide). DISCUSSION: In patients with Parkinson's disease, as little as 10 mg of pyridoxine may reverse the clinical benefits as well as the adverse effects of levodopa. Coadministration of levodopa with either carbidopa or benserazide has minimized the effects of this interaction.	INBRIJA, LEVODOPA

Drug Interaction

Drug Names

Levodopa/Pyridoxine

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Pyridoxine increases levodopa metabolism, decreasing the amount of levodopa available to the central nervous system.

CLINICAL EFFECTS: The pharmacologic effects of levodopa may be decreased.

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Avoid pyridoxine in patients receiving levodopa alone; however, the interaction can be minimized by giving levodopa with a peripheral decarboxylase inhibitor (e.g. carbidopa, benserazide).

DISCUSSION: In patients with Parkinson's disease, as little as 10 mg of pyridoxine may reverse the clinical benefits as well as the adverse effects of levodopa. Coadministration of levodopa with either carbidopa or benserazide has minimized the effects of this interaction.

INBRIJA, LEVODOPA

Severe List
Autoimmune disease
Systemic lupus erythematosus

The following adverse reaction information is available for MELATONIN-B6 (PYRIDOXAL PHOS) (melatonin/pyridoxal phosphate):

Overview
Severe
Less Severe

Adverse reaction overview.

No enhanced Common Adverse Effects information available for this drug.

There are 0 severe adverse reactions.

There are 15 less severe adverse reactions.

More Frequent	Less Frequent
Dizziness Headache disorder Sedation hangover effect	Abdominal pain with cramps Acute cognitive impairment CNS depression Concentration difficulty Depression Hypotension Irritability Nausea Symptoms of anxiety Tremor Vomiting

Rare/Very Rare
Panic disorder

The following precautions are available for MELATONIN-B6 (PYRIDOXAL PHOS) (melatonin/pyridoxal phosphate):

Pediatric
Pregnant
Lactation
Geriatric

No enhanced Pediatric Use information available for this drug.

Contraindicated

None

Severe Precaution

None

Management or Monitoring Precaution

None

No enhanced Pregnancy information available for this drug.

No enhanced Lactation information available for this drug.

No enhanced Geriatric Use information available for this drug.